特布他林联合异丙托溴铵雾化吸入辅助治疗慢性阻塞性肺疾病稳定期的疗效及对患者呼吸功能的影响

Efficacy of terbutaline combined with ipratropium bromide in the treatment of chronic obstructive pulmonary disease at stable stage and its effect on respiratory function of patients

目的观察特布他林联合异丙托溴铵雾化吸入辅助治疗慢性阻塞性肺疾病稳定期的疗效及对患者呼吸功能的影响。方法选取2017年1月-2019年3月广东省东莞市虎门镇南栅医院收治的慢性阻塞性肺疾病稳定期患者116例,依据入院先后分为2组,各58例。对照组行常规治疗,观察组在对照组基础上予特布他林联合异丙托溴铵雾化吸入治疗。对比2组临床疗效、治疗前后呼吸功能[第1秒呼出量(FEV1)占预计值的百分比、FEV1/用力肺活量(FVC)及FVC]及不良反应。结果观察组治疗总有效率为94.83%,高于对照组的70.69%(χ^(2)=11.841,P=0.000)。治疗后,2组FEV1占预计值百分比、FEV1/FVC及FVC均高于治疗前,且观察组高于对照组(P <0.01)。2组不良反应总发生率比较差异无统计学意义(χ^(2)=1.914,P=0.166)。结论特布他林联合异丙托溴铵雾化吸入辅助治疗慢性阻塞性肺疾病稳定期疗效较好,虽与常规治疗不良反应基本相当,但其对患者呼吸功能改善效果更好,临床价值更高。

Objective To observe the effect of nebulized terbutaline combined with ipratropium bromide in the treatment of chronic obstructive pulmonary disease at stable stage and its effect on patients’ respiratory function. Methods A total of 116 stable copd patients admitted to Nanzha Hospital,Humen Town,Dongguan City,Guangdong Province from January 2017 to March 2019 were selected. The patients were divided into 2 groups,each of 58 cases. The control group received routine treatment,and the observation group received terbutaline atomization inhalation combined with ipratropium bromide treatment based on the control group. Compared two groups of clinical curative effect,respiratory function[forced expiratory volume in one second( FEV1) percent of expected value,FEV1/forced vital capacity( FVC) and FVC]before and after the treatment,and adverse reactions. Results Observation group treatment the total effective rate was 94. 83%,higher than that of control group 70. 69%( χ^(2)= 11. 841,P = 0. 000). After treatment,2 groups of FEV1 percent of expected value,FEV1/FVC and FVC were higher than before the treatment,and the observation group was higher than control group( P < 0. 01). Incidence of adverse reactions to the total in the 2 groups there was no statistically significant difference comparing( χ^(2)= 1. 914,P =0. 166). Conclusion Terbutaline nebulized inhalation combined with ipratropium bromide as adjuvant therapy for patients with chronic obstructive pulmonary disease at stable stage has a clear effect. Although it is basically the same as the adverse reactions of conventional treatment,it has a better effect on patients’ respiratory function and a higher clinical value.